Predictive Biosciences, Inc announced that it will be completing the study of Urine-based Diagnostic Assay by March 2011.
Urine-based Diagnostic Assay is non-invasive that employs patented clinical algorithms (i.e., ClDD, or Clinical Intervention Determining Diagnostic) enabling physicians to reliably determine the presence or absence of cancer, so that additional follow-up may be accelerated (if cancer is detected) or avoided (if a patient is cancer-free).
The purpose of this study is to detect recurrent bladder cancer using a combination of protein and DNA biomarkers in urine. This 1000 patient study is not yet open for participant recruitment. The official title of the study is “Phase 3 Study of Bladder Cancer Recurrence Surveillance”.